USING THE BIOPHYSICS OF BLOOD SERUM PROTEINS FOR DISEASE DIAGNOSIS
Albutran is an American in vitro diagnostics development company. Our mission is to enable accurate diagnosis of cancer and sepsis, very early, when the disease damage is minimal and treatment is most effective.
Our technology uses microwave spectroscopy to investigate human serum albumin in patient blood samples.
Analyzing the microwave-sensitive biophysical properties of blood serum, Albutran’s in vitro diagnostic system provides the physician with new, critical diagnostic information having higher granularity, preparing him to more effectively optimize patient treatment, patient post-treatment, and patient outcomes.
WHO WE ARE
-
• Diagnosis (early detection)
• Prognosis
• Treatment management
-
• Diagnosis (early detection)
• Prognosis
• Treatment management
Disease Diagnostics by Albutran using the microwave-sensitive, biophysical properties of blood serum proteins for disease diagnosis of:
“ATA-test” for Cancer
The ATA-test for cancer is the culmination of Albutran’s identification of biomarkers that accurately detect onset of aggressive, life-threatening cancers, and especially differentiate from non-life-threatening tumors.
Technology
Albutran rapid diagnosis of cancer malignancy employs the Albutran EPR (Electron Paramagnetic Resonance) spectrometer. A 6-minute scan of the patient’s blood serum sample, detects the presence (or absence) of life-threatening growth of malignant cancer in the patient, with a sensitivity of 90% and a specificity of 90% (false negative of 10% and false positive of 10%).
Measured Parameter (DR)
Albumin Conformation Index (the measured, microwave-sensitive parameter of human serum albumin for active cancer malignancy)
“ATA-TEST” FOR CANCER
DR less than 1.0 can be used for
Diagnosis
• onset — very early screening of the onset of life-threatening cancer
Diagnosis
• confirming life-threatening of the malignancy indicated by other diagnostic methods
Prognosis
• post surgery — some active malignant material remains
Prognosis
• trending up — treatment effective; should continue
Prognosis
• trending down — treatment ineffective; should be modified
DR greater than 1.0 can be used for
Diagnosis
• no aggressive malignancy detected — the patient is cancer-free: a health test
Prognosis
• trending up — aggressive malignancy no longer detected — patient in remission
“ATA-test” for Sepsis
An effective test for sepsis should diagnose sepsis at the initial stage of the disease - at the stage of accumulation of excess toxins in the blood, before the onset of symptoms that occur after prolonged exposure to toxins in the patient's body.
Technology
Albutran has developed an in vitro blood test that can be performed in 30 minutes, which employs the Albutran EPR (Electron Paramagnetic Resonance) spectrometer. The Albutran test accurately detects the onset of sepsis in a sepsis-risk patient one to two days earlier than current tests. A 3-minute scan of the patient’s blood serum sample, detects the existence (or absence) of beginning sepsis in the patient, with a sensitivity of 80% and a specificity of 80% (false negative of 20% and false positive of 20%).
Measured Parameter (DTE)
Detoxifying Efficiency (as a % - the measured, microwave-sensitive parameter of human serum albumin for Toxicity)
“ATA-TEST” FOR SEPSIS
A low value of DTE can be used for
Diagnosis
• onset - very early screening of the onset of beginning sepsis
Diagnosis
• confirming sepsis indicated by other diagnostic methods
Prognosis
• trending higher - treatment effective; should continue
Prognosis
• trending lower - treatment ineffective; should be modified
A high value of DTE can be used for
Diagnosis
• no sepsis detected - the patient has no risk to develop sepsis: not a critical patient
Prognosis
• trending higher - sepsis no longer detected - patient has recovered
TECHNOLOGY
LABORATORY ANALYZER “EPR AXM-09”
Our technology uses microwave spectroscopy to investigate human serum albumin in patient blood samples.
Albutran USA, LLC
Lee Smith, PhD.
Houston, TX
(713) 854-6660
lee.smith@albutran.com
General Inquiries
info@albutran.com
Are you a clinical research center interested in collaborating with Albutran on a study? Please contact bd@albutran.com
CONTACT US
Our Team
Lee Smith, PhD.
General Manager
Joseph Gibson, MBA, PhD.
Consultant, Healthcare Business Start-ups
Vladimir Muravsky, PhD.
Inventor, Founder, CSO, CTO